Related Experiment Video
Updated: Jun 27, 2026
05:11
Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
Published on: May 10, 2024
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001
Scott Parker1, Jill Schriewer, Christina Oberle
1Department of Molecular Microbiology and Immunology, St Louis University Medical School, St Louis, MO, USA.
Antiviral Therapy
|December 3, 2008
Summary
A single dose of CMX001 effectively treats lethal mousepox by reducing viral load and key disease markers. This antiviral treatment shows promise for managing poxvirus infections, including potential smallpox or monkeypox outbreaks.
Area of Science:
- Virology
- Infectious Diseases
- Biomarker Discovery
Background:
- Emerging threats of human monkeypox and bioterrorism necessitate new antiviral therapies.
- Characteristic rash is an early indicator for smallpox and monkeypox.
- Biomarkers are crucial for monitoring disease and evaluating treatment efficacy.
Purpose of the Study:
- To evaluate biomarkers for disease staging in a lethal mousepox model.
- To determine the optimal dosing regimen for CMX001 in treating mousepox.
Main Methods:
- Mice were infected with ectromelia virus and treated with varying doses of CMX001.
- Disease progression was monitored using weight loss, blood interferon-gamma, liver enzymes (ALT, AST), viral DNA, and neutrophil counts.
Main Results:
- A single 25 mg/kg dose of CMX001 administered on days 4 or 5 post-infection proved efficacious.
- This treatment significantly reduced ALT, interferon-gamma, and viral DNA in infected mice.
- Biomarkers were successfully used to establish optimal CMX001 dosing.
Conclusions:
- CMX001 demonstrates efficacy as a single-dose treatment for mousepox.
- Identified biomarkers can effectively monitor disease progression and antiviral efficacy.
- These findings support potential use in human monkeypox or smallpox outbreaks.
